Rosenberg, Michael

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Myostatin Inhibits IGF-I-Induced Myotube Hypertrophy through Akt

Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A., & Rosenzweig, A. (2009) · American Journal of Physiology-Cell Physiology

Muscle Physiology and DisordersMuscle metabolism and nutrition

Cited by 231

Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: A pilot study

ROSENBERG, M. A., SAMUEL, M., THOSANI, A., & ZIMETBAUM, P. J. (2013) · Pacing and Clinical Electrophysiology

Atrial Fibrillation Management and OutcomesECG Monitoring and Analysis

Cited by 179

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118